In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.

Rapivab (peramivir) - BioCryst Pharmaceuticals

Inavir (laninamivir) - Daiichi Sankyo

Relenza (zanamivir) - GSK, Vaxart

Xofluza (baloxavir marboxil) - Roche

http://www.ncbi.nlm.nih.gov/pubmed/42243334

Akeno Tsuneki-Tokunaga; Alfredo A Hinay; Koyuki Atifa Rahmi; Kyosuke Kanai; Seiji Kageyama; Waldy Yudha Perdana

Jun 5, 2026